加载中
NASDAQHealthcareBiotechnology
最新数据
US$5.87
−US$0.08 · -1.34%
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
常规交易时段
US$5.90
−US$0.05 · -0.84%
盘中时间采用ET。市场数据可能有所延迟。
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
日内区间
当前US$5.90
52周区间
当前US$5.90
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
73
低估
情绪
56
多空交织
风险
52
风险偏高
动量
36
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
日内区间
当前US$5.90
52周区间
当前US$5.90
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3348.2万 USD | 263.8万 USD | 276万 USD | 353.3万 USD | −78.2万 USD |
| 销货成本 | 19万 USD | 20.4万 USD | 18.6万 USD | 32.2万 USD | 19.9万 USD |
| 毛利 | 3329.2万 USD | 243.4万 USD | 257.4万 USD | 321.1万 USD | −98.1万 USD |
| 研究与开发 | 5818.5万 USD | 4280.4万 USD | 3382.2万 USD | 2194.5万 USD | 1289万 USD |
| 销售、一般及管理费用 | 2691.4万 USD | 2393.1万 USD | 2025.8万 USD | 1392.3万 USD | 792.8万 USD |
| 营业费用 | 8509.9万 USD | 6673.5万 USD | 5408万 USD | 3586.8万 USD | 2081.8万 USD |
| 利息收入 | — | 335.6万 USD | 384.9万 USD | 5万 USD | — |
| 利息支出 | 114.8万 USD | — | — | — | 92.7万 USD |
| 折旧和摊销 | 32.7万 USD | 30.8万 USD | 28.7万 USD | 22.2万 USD | 18.1万 USD |
| 营业利润 | −5180.7万 USD | −6430.1万 USD | −5150.6万 USD | −3265.7万 USD | −2179.9万 USD |
| 净利润 | −5270.1万 USD | −6102.4万 USD | −4912万 USD | −3360.8万 USD | −2301.4万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI740.91万0.00%2.3万亿 USD0.03%US$382.06+0.03%
iShares Russell 2000 ETFIWM591.86万0.01%787.4亿 USD0.19%US$278.6-0.12%
Vanguard Extended Market ETFVXF251.31万0.00%954亿 USD0.05%US$234.38-0.27%
iShares Russell 2000 Growth ETFIWO221.85万0.02%139.17亿 USD0.24%US$354.85-0.54%
Schwab U.S. Small-Cap ETFSCHA132.9万0.01%218.24亿 USD0.03%US$32.775-0.05%
Simplify Propel Opportunities ETFSURI130.54万1.72%7606.44万 USD2.82%US$17.21720.00%
Vanguard Russell 2000 ETFVTWO115.78万0.01%180亿 USD0.06%US$112.54-0.11%
iShares Micro-Cap ETFIWC74.2万0.06%13.17亿 USD0.60%US$182.38-0.34%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHASimplify Propel Opportunities ETFSURIVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
